Revita DMR granted FDA Breakthrough Device Designation for T2DMFractyl Laboratories has announced that the FDA has granted Breakthrough Device Designation for Revita DMR (duodenal mucosal resurfacing)...
First patient enrolled in pivotal REVITA-T2Di study for T2DMFractyl Laboratories has announced the enrolment of the first patient in a pivotal clinical trial of Revita DMR (duodenal mucosal...
INSPIRE: Revita DMR plus GLP-1RA shows durable insulin-free glycaemic controlOutcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a...